News Novartis Presents Impressive Gilenya Updates at MSBoston 2014 Novartis Presents Impressive Gilenya Updates at MSBoston 2014 by Patricia Silva, PhD | September 12, 2014 Share this article: Share article via email Copy article link This past Wednesday, September 10th, the largest, most anticipated multiple sclerosis (MS) convention — the 6th Joint ACTRIMS-ECTRIMS Triennial Meeting, MSBoston 2014 — kicked off with a whopping 8,000 registered attendees, all eager to learn more about the latest developments in MS. One of the highlights of the event was Swiss pharmaceutical giantĀ Novartis’ presentation on their leading product for MS – Gilenya (fingolimod). Their recently-concluded follow-up study,Ā LONGTERMS, showcased the drug’s sustained efficacy even years into treatment. Prior to this study, Novartis researchers gathered patient data fromĀ FREEDOMS, a Phase III core study, and noted that the likelihood of worsening of disabilities in 4 years increased in MS patients with significant brain volume loss in 2 years. Findings from the LONGTERMS experiment showed Gilenya to be quite promising, as MS patients receiving the drug showed reduced and stabilized brain volume loss at 6 years, measured at 0.33%-0.46% – values similar to healthy patients. Gilenya has had a good start into the MS market, leading the drug company’s sales during the first half of the year with sales totaling $1.1 billion — an increase of about 30% from last year’s sales. Novartis is also marketing an injectable for MS called Extavia (interferon beta-1b). Together with medical device company Owen Mumford, Extavia may be used with aĀ new injective drug delivery systemĀ called theĀ ExtaviProĀ® 30G auto-injector.Ā Additionally, the company is working on a third product candidate for MS called BAF312 (siponimod), which may become a pioneer oral treatment for secondary progressive MS. Several other pharmaceutical companies have presented or are scheduled to present updates on their own portfolio for MS. Biogen Idec alone will be making a total of 90 presentations during the convention. [adrotate group=”4″] Print This Page About the Author Patricia Silva, PhD PatrĆcia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. PatrĆcia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles. Tags 2014 ACTRIMS-ECTRIMS Meeting, Extavia, Fingolimod, Gilenya, Novartis, siponimod
April 18, 2024 News by Marisa Wexler, MS AAN 2024: Sustained myelin, nerve cell gains with long-term CNM-Au8
April 18, 2024 News by Lindsey Shapiro, PhD AAN 2024: Ocrevus benefits Black, Hispanic patients same as whites
April 17, 2024 News by Marisa Wexler, MS AAN 2024: Fertility treatment in MS doesn’t increase relapse risk